Skip to main content
. 2016 Dec 27;23(1):19–25. doi: 10.5761/atcs.oa.16-00164

Table 2.

Comparison of clinicopathological features between PBAC and non-PBAC patients

  PBAC (+) (n = 24) PBAC (−) (n = 70) p valuesa

Mean age (range) 66.3 (50–74) 69.6 (51–82) 0.043b
Male (%) 22 (91.7) 62 (88.6) 0.967
Current ex-smoker (%) 24 (100) 69 (98.6) 0.573
Comorbidity incidence (%) 11 (45.8) 39 (55.7) 0.403
 Cardiac diseases 0 7 (10.0) 0.246
 Other cancers 5 (20.8) 13 (18.6) 0.954
 Chronic hepatitis 0 4 (5.7) 0.541
 Respiratory dysfunctions 7 (29.2) 26 (37.1) 0.480
Tumor size (mm) 49.2 39.1 0.008b
Surgical procedures (%)      
 Lobectomy 23 (95.8) 61 (87.1)  
 Pneumonectomy 1 (4.2) 6 (8.6)  
 Segmentectomy 0 3 (4.3) 0.352
Pathological stage (%)      
 p Stage IIA 12 (50.0) 38 (54.3)  
 p Stage IIB 5 (20.8) 15 (21.4)  
 p Stage IIIA 7 (29.2) 17 (24.3) 0.891
Lymphatic invasion (%) 6 (25.0) 27 (38.6) 0.229
Vascular invasion (%) 20 (83.3) 53 (75.7) 0.625
Pleural invasion 9 (37.5) 23 (32.9) 0.679
Pathological N status (%)      
 pN0 1 (4.2) 8 (11.4)  
 pN1 18 (75.0) 47 (67.1)  
 pN2 5 (20.8) 15 (21.4) 0.564
Recurrent (%) 6 (25.0) 15 (21.4) 0.717
 Distant metastasis 1 (16.7) 4 (26.7)  
 Locoregional 6 (100) 11 (73.3) 0.921

PBAC: platinum-based adjuvant chemotherapy. aFisher’s exact test; bStudent’s t-test.